Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:60079 |
Name | Her2-receptor positive breast cancer |
Definition | A breast cancer that is characterized by the presence of Her2 receptors. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer Her2-receptor positive breast cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA wild-type | Buparlisib + Trastuzumab | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 pos PIK3CA act mut | Buparlisib + Trastuzumab | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | Buparlisib + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 pos PIK3CA act mut | Trastuzumab | Her2-receptor positive breast cancer | decreased response | detail... |
ERBB2 amp | Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Neratinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Margetuximab-cmkb | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | MM-302 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Sunitinib + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | HER2 Vaccine | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | Oxaliplatin + Tegafur-gimeracil-oteracil Potassium + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Capecitabine + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Everolimus + Trastuzumab + Vinorelbine | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Oxaliplatin + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 T798M | Lapatinib | Her2-receptor positive breast cancer | resistant | detail... |
ERBB2 over exp PIK3CA H1047R | Trastuzumab | Her2-receptor positive breast cancer | resistant | detail... |
ERBB2 over exp PIK3CA H1047R | Bevacizumab + Buparlisib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp PIK3CA H1047R | Buparlisib + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp PIK3CA H1047R | Lapatinib + Trastuzumab | Her2-receptor positive breast cancer | resistant | detail... |
ERBB2 over exp PIK3CA H1047R | Pertuzumab + Trastuzumab | Her2-receptor positive breast cancer | resistant | detail... |
ERBB2 over exp PIK3CA H1047R | Buparlisib + Pertuzumab + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp PIK3CA H1047R | Buparlisib + Lapatinib + Trastuzumab | Her2-receptor positive breast cancer | no benefit | detail... |
PIK3CA mutant | CCT128930 | Her2-receptor positive breast cancer | sensitive | detail... |
FGFR1 amp | Dovitinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Copanlisib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp PIK3CA mut | Copanlisib | Her2-receptor positive breast cancer | sensitive | detail... |
FGFR2 amp | Dovitinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Ado-trastuzumab emtansine | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | NAX014 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Afatinib + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp PIK3CA mut | PKI-179 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | CUDC-101 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Varlitinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Tucatinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Margetuximab-cmkb | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Palbociclib + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Lapatinib + Palbociclib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp PIK3CA E545K PIK3CA K567R | Gedatolisib | Her2-receptor positive breast cancer | sensitive | detail... |
Unknown unknown | BMS-906024 | Her2-receptor positive breast cancer | not applicable | detail... |
PIK3CA wild-type | Lapatinib + Paclitaxel + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Ado-trastuzumab emtansine + Tucatinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | Trastuzumab + Tucatinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | Capecitabine + Tucatinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | Capecitabine + Trastuzumab + Tucatinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | Trodusquemine | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Trazimera | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 pos PIK3CA mut | AT13148 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Lapatinib + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 pos PIK3CA mut | Lapatinib + Trastuzumab | Her2-receptor positive breast cancer | decreased response | detail... |
ERBB2 positive | Ado-trastuzumab emtansine + Docetaxel | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Ado-trastuzumab emtansine + Docetaxel + Pertuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 pos PIK3CA act mut | Palbociclib + Pictilisib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Lapatinib + MK2206 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | CDX-3379 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | CDX-3379 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | CDX-3379 + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Entinostat + Lapatinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 amp | Entinostat + Lapatinib + Trastuzumab | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | MYL-1401O + Paclitaxel | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 pos PIK3CA mut | Capecitabine + Lapatinib | Her2-receptor positive breast cancer | decreased response | detail... |
ERBB2 pos PIK3CA K111N | Ado-trastuzumab emtansine | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 pos PIK3CA I391M | Ado-trastuzumab emtansine | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 pos PIK3CA C420R | Ado-trastuzumab emtansine | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 pos PIK3CA H1047R | Ado-trastuzumab emtansine | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 pos PIK3CA E545K | Ado-trastuzumab emtansine | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Disitamab vedotin | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | TAK-285 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | BGB-283 | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 over exp | ADXS31-164 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Ibrutinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
Unknown unknown | Abemaciclib + Lapatinib | Her2-receptor positive breast cancer | not applicable | detail... |
Unknown unknown | Abemaciclib | Her2-receptor positive breast cancer | not applicable | detail... |
Unknown unknown | Abemaciclib + Trastuzumab | Her2-receptor positive breast cancer | not applicable | detail... |
ERBB2 over exp | Lapatinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Trastuzumab deruxtecan | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp PIK3CA mut | Ipatasertib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 pos PIK3CA mut | Lapatinib | Her2-receptor positive breast cancer | decreased response | detail... |
ERBB2 pos PIK3CA mut | Trastuzumab | Her2-receptor positive breast cancer | decreased response | detail... |
ARID1A loss | Trastuzumab | Her2-receptor positive breast cancer | resistant | detail... |
ARID1A loss | AZD8055 | Her2-receptor positive breast cancer | resistant | detail... |
ERBB2 positive | Neratinib + Paclitaxel | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Pyrotinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 mutant | Neratinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Metformin | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | Pertuzumab + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Capecitabine + Neratinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | CT-P6 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | KRIBB11 + MK2206 | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | ZW25 | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | Poziotinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | SB3 | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 over exp | Trastuzumab-anns | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | HER2 BATs | Her2-receptor positive breast cancer | sensitive | detail... |
Unknown unknown | S63845 | Her2-receptor positive breast cancer | not applicable | detail... |
ERBB2 amp | S63845 + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Lapatinib + S63845 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 L755S ERBB2 amp | Lapatinib | Her2-receptor positive breast cancer | resistant | detail... |
ERBB2 L755S | Lapatinib | Her2-receptor positive breast cancer | resistant | detail... |
ERBB2 L755S ERBB2 amp | Lapatinib + Trastuzumab | Her2-receptor positive breast cancer | resistant | detail... |
ERBB2 L755S ERBB2 amp | Pertuzumab + Trastuzumab | Her2-receptor positive breast cancer | resistant | detail... |
ERBB2 L755S ERBB2 amp | Ado-trastuzumab emtansine | Her2-receptor positive breast cancer | conflicting | detail... |
ERBB2 L755S ERBB2 amp | Afatinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 L755S ERBB2 amp | Neratinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Carboplatin + Docetaxel + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Carboplatin + Docetaxel + Pertuzumab + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Paclitaxel + Pertuzumab + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Paclitaxel + Pertuzumab + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | MEDI4276 | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 over exp | Ado-trastuzumab emtansine | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Ado-trastuzumab emtansine | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | ARX-788 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | trastuzumab and hyaluronidase-oysk injection | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | trastuzumab and hyaluronidase-oysk injection | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 Y772_A775dup ERBB2 amp | Neratinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 D769Y ERBB2 amp | Neratinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 V777L ERBB2 amp | Neratinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 D769Y ERBB2 amp | Trastuzumab | Her2-receptor positive breast cancer | resistant | detail... |
ERBB2 D769Y ERBB2 amp | Lapatinib | Her2-receptor positive breast cancer | resistant | detail... |
ERBB2 L755S ERBB2 amp | Trastuzumab | Her2-receptor positive breast cancer | decreased response | detail... |
ERBB2 R456C ERBB2 amp | Neratinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 L313I ERBB2 amp | Neratinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | GBR1302 | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 amp | TAS0728 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Pertuzumab + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Pertuzumab + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Trastuzumab + Vinorelbine | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Trastuzumab + Vinorelbine | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Lapatinib + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Neratinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Neratinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Docetaxel + Pertuzumab + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Docetaxel + Pertuzumab + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 pos PIK3CA mut | Neratinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 pos PIK3CA amp | Neratinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 pos PIK3CA H1047R | Neratinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 pos PIK3CA E542K | Neratinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 pos PIK3CA E545K | Neratinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 pos PIK3CA E545D | Neratinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | Capecitabine + Pyrotinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 amp PIK3CA act mut | Poziotinib | Her2-receptor positive breast cancer | decreased response | detail... |
ERBB2 over exp PIK3CA act mut | Poziotinib | Her2-receptor positive breast cancer | decreased response | detail... |
ERBB2 amp PIK3CA E542X | Poziotinib | Her2-receptor positive breast cancer | decreased response | detail... |
ERBB2 over exp PIK3CA E542X | Poziotinib | Her2-receptor positive breast cancer | decreased response | detail... |
ERBB2 over exp PIK3CA E545X | Poziotinib | Her2-receptor positive breast cancer | decreased response | detail... |
ERBB2 amp PIK3CA E545X | Poziotinib | Her2-receptor positive breast cancer | decreased response | detail... |
ERBB2 amp PIK3CA H1047X | Poziotinib | Her2-receptor positive breast cancer | decreased response | detail... |
ERBB2 over exp PIK3CA H1047X | Poziotinib | Her2-receptor positive breast cancer | decreased response | detail... |
ERBB2 amp | Poziotinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 amp PIK3CA wild-type | Poziotinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 amp | Carboplatin + Paclitaxel + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Carboplatin + Paclitaxel + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Docetaxel + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Docetaxel + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Capecitabine + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Capecitabine + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Capecitabine + Lapatinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Capecitabine + Lapatinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Lapatinib + Trastuzumab | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Capecitabine + Neratinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Trastuzumab-anns | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Trastuzumab deruxtecan | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Trastuzumab deruxtecan | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Capecitabine + Neratinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | MBS301 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 G778_P780dup | Lapatinib | Her2-receptor positive breast cancer | predicted - resistant | detail... |
ERBB2 over exp | Capecitabine + Trastuzumab + Tucatinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Capecitabine + Trastuzumab + Tucatinib | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Margetuximab-cmkb + MGD013 | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | Abemaciclib + Fulvestrant + Trastuzumab | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
PIK3CA mutant | Ado-trastuzumab emtansine | Her2-receptor positive breast cancer | not predictive | detail... |
ERBB2 over exp | Pertuzumab/trastuzumab/hyaluronidase-zzxf | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Pertuzumab/trastuzumab/hyaluronidase-zzxf | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | Docetaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Docetaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 positive | Ado-trastuzumab emtansine + Capecitabine | Her2-receptor positive breast cancer | no benefit | detail... |
ERBB2 over exp | Entinostat + Lapatinib + Trastuzumab | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 over exp | Entinostat + Lapatinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | Epertinib + Trastuzumab | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 positive | Trastuzumab + Vinorelbine | Her2-receptor positive breast cancer | no benefit | detail... |
ERBB2 over exp | ARX-788 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 over exp | CT-P6 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | CT-P6 | Her2-receptor positive breast cancer | sensitive | detail... |
ERBB2 amp | Margetuximab-cmkb | Her2-receptor positive breast cancer | sensitive | detail... |
Unknown unknown | CYC065 | Her2-receptor positive breast cancer | not applicable | detail... |
ERBB2 L755S ERBB2 amp | Trastuzumab + Vinorelbine | Her2-receptor positive breast cancer | predicted - resistant | detail... |
ERBB2 L755S ERBB2 amp | Docetaxel + Pertuzumab + Trastuzumab | Her2-receptor positive breast cancer | predicted - resistant | detail... |
ERBB2 L755S ERBB2 amp | Capecitabine + Lapatinib | Her2-receptor positive breast cancer | predicted - resistant | detail... |
ERBB2 L755S ERBB2 amp | Trastuzumab deruxtecan | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
ERBB2 amp | Ado-trastuzumab emtansine + Neratinib | Her2-receptor positive breast cancer | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00411788 | Phase II | Sirolimus + Trastuzumab | A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer | Completed | USA | 0 |
NCT00574587 | Phase Ib/II | Paclitaxel + Vorinostat Trastuzumab Cyclophosphamide + Doxorubicin | Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis | Completed | USA | 0 |
NCT01016886 | Phase Ib/II | Bisoprolol Perindopril | Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research | Unknown status | CAN | 0 |
NCT01118975 | Phase Ib/II | Lapatinib + Vorinostat | GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers | Terminated | USA | 0 |
NCT01160211 | Phase III | Lapatinib + Trastuzumab Letrozole Anastrozole Lapatinib Trastuzumab Exemestane | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | Active, not recruiting | USA | CAN | 36 |
NCT01177397 | Phase Ib/II | Onatasertib | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | Completed | USA | 3 |
NCT01273610 | Phase II | Lapatinib + Trastuzumab | Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT01276041 | Phase II | Paclitaxel + Pertuzumab + Trastuzumab | Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer | Completed | USA | 0 |
NCT01300962 | Phase I | Buparlisib + Capecitabine + Lapatinib Buparlisib + Capecitabine + Trastuzumab Buparlisib + Capecitabine Alpelisib + Capecitabine | Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | Completed | USA | 0 |
NCT01305941 | Phase II | Everolimus + Trastuzumab + Vinorelbine | A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases | Completed | USA | 0 |
NCT01325207 | Phase Ib/II | Trastuzumab | Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer | Completed | USA | 0 |
NCT01358877 | Phase III | Pertuzumab Epirubicin Cyclophosphamide Paclitaxel Docetaxel Trastuzumab Fluorouracil Carboplatin Doxorubicin | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY) | Active, not recruiting | USA | CAN | 40 |
NCT01434303 | Phase I | Entinostat + Lapatinib + Trastuzumab | Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only | Completed | USA | 0 |
NCT01491737 | Phase II | Anastrozole Letrozole Trastuzumab Pertuzumab + Trastuzumab | A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (PERTAIN) | Completed | USA | 7 |
NCT01494662 | Phase II | Capecitabine + Neratinib Neratinib | HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | Recruiting | USA | 0 |
NCT01513083 | Phase I | Ado-trastuzumab emtansine | A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function | Completed | USA | CAN | 3 |
NCT01526473 | Phase I | AVX901 | A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 | Completed | USA | 0 |
NCT01565083 | Phase II | Pertuzumab + Trastuzumab + Vinorelbine | A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer | Completed | USA | 6 |
NCT01566721 | Phase III | Trastuzumab | A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer) | Completed | CAN | 58 |
NCT01602406 | Phase I | Elgemtumab + Trastuzumab | Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer | Completed | USA | 8 |
NCT01622868 | Phase II | Lapatinib | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer | Active, not recruiting | USA | CAN | 1 |
NCT01702558 | Phase II | Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Capecitabine | A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer | Terminated | CAN | 11 |
NCT01702571 | Phase III | Ado-trastuzumab emtansine | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | Completed | CAN | 42 |
NCT01730118 | Phase I | HER2 Vaccine | Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | Completed | USA | 0 |
NCT01772472 | Phase III | Ado-trastuzumab emtansine Trastuzumab | A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) | Active, not recruiting | USA | CAN | 26 |
NCT01783756 | Phase Ib/II | Capecitabine + Everolimus + Lapatinib | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | Completed | USA | 0 |
NCT01796197 | Phase II | Cyclophosphamide + Doxorubicin Pertuzumab + Trastuzumab Paclitaxel | Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa | Unknown status | USA | 0 |
NCT01808573 | Phase III | Capecitabine + Lapatinib Capecitabine + Neratinib | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA) | Completed | USA | CAN | 26 |
NCT01816035 | Phase I | Ado-trastuzumab emtansine | Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT01828021 | Phase II | Margetuximab-cmkb | Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer | Completed | USA | 0 |
NCT01848756 | Phase Ib/II | SNX-5422 | Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers | Terminated | USA | 0 |
NCT01853748 | Phase II | Paclitaxel + Trastuzumab Ado-trastuzumab emtansine | T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) | Active, not recruiting | USA | 0 |
NCT01855828 | Phase II | Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Epirubicin + Fluorouracil + Pertuzumab + Trastuzumab | Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | Completed | USA | 0 |
NCT01873833 | Phase II | Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT01875666 | Phase I | Lapatinib + Trastuzumab Trastuzumab Pertuzumab Pertuzumab + Trastuzumab | Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib | Completed | USA | 0 |
NCT01901146 | Phase III | Cyclophosphamide + Epirubicin Paclitaxel + Trastuzumab | Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac) | Completed | CAN | 17 |
NCT01904903 | Phase II | Pertuzumab Ado-trastuzumab emtansine Trastuzumab | Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt) | Completed | USA | 0 |
NCT01912963 | Phase II | Eribulin Pertuzumab Trastuzumab | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer | Terminated | USA | 0 |
NCT01921335 | Phase I | Trastuzumab + Tucatinib | ARRY-380 + Trastuzuamab for Breast w/ Brain Mets | Active, not recruiting | USA | 0 |
NCT01922921 | Phase Ib/II | HER-2/neu intracellular domain protein + Pertuzumab + Polysaccharide-K + Trastuzumab HER-2/neu intracellular domain protein + Pertuzumab + Trastuzumab | Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy | Unknown status | USA | 0 |
NCT01924351 | Phase II | HER2-positive Breast Cancer With Brain Metastasis (GCC 1345) | Withdrawn | USA | 0 | |
NCT01934894 | Phase II | Cabazitaxel + Lapatinib | Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases | Terminated | USA | 0 |
NCT01937117 | Phase II | Pertuzumab + Trastuzumab | Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT01966471 | Phase III | Cyclophosphamide + Docetaxel + Doxorubicin + Epirubicin + Fluorouracil + Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Epirubicin + Fluorouracil + Pertuzumab + Trastuzumab | A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | Active, not recruiting | USA | CAN | 34 |
NCT01976169 | Phase I | Ado-trastuzumab emtansine + Palbociclib | Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) | Active, not recruiting | USA | 0 |
NCT01983501 | Phase I | Ado-trastuzumab emtansine + Tucatinib | A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer | Completed | USA | CAN | 0 |
NCT01989676 | Phase III | Paclitaxel + Trastuzumab Paclitaxel + Trazimera | A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) | Completed | USA | 23 |
NCT02000596 | Phase II | Pertuzumab + Trastuzumab Anastrozole + Fulvestrant | Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC | Terminated | USA | 0 |
NCT02003209 | Phase III | Carboplatin + Docetaxel + Goserelin + Pertuzumab + Trastuzumab Carboplatin + Docetaxel + Pertuzumab + Trastuzumab | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | Active, not recruiting | USA | 1 |
NCT02014909 | Phase I | CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | Completed | USA | 0 |
NCT02025192 | Phase I | Capecitabine + Trastuzumab + Tucatinib Trastuzumab + Tucatinib Capecitabine + Tucatinib | A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer | Completed | USA | 0 |
NCT02038010 | Phase I | Ado-trastuzumab emtansine + Alpelisib | BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx | Completed | USA | 0 |
NCT02057133 | Phase I | Abemaciclib + Loperamide + Pertuzumab + Trastuzumab Abemaciclib + Fulvestrant + LY3023414 Abemaciclib + Letrozole Abemaciclib + Exemestane Abemaciclib Abemaciclib + Everolimus + Exemestane Abemaciclib + Anastrozole Abemaciclib + Tamoxifen Abemaciclib + Trastuzumab | A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | Active, not recruiting | USA | 0 |
NCT02060253 | Phase I | Ganetespib + Paclitaxel + Trastuzumab | Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer | Completed | USA | 0 |
NCT02061332 | Phase Ib/II | HER2-pulsed DC1 vaccine | DC Vaccine for Patients With Ductal Carcinoma In Situ | Completed | USA | 0 |
NCT02063724 | Phase I | HER2-pulsed DC1 vaccine | HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant) | Active, not recruiting | USA | 0 |
NCT02066532 | Phase Ib/II | Ruxolitinib + Trastuzumab | Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT02073487 | Phase II | Paclitaxel Ado-trastuzumab emtansine + Lapatinib Lapatinib + Trastuzumab Nab-paclitaxel | Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel | Completed | USA | 0 |
NCT02073916 | Phase I | Ado-trastuzumab emtansine + Lapatinib + Nab-paclitaxel | TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer | Completed | USA | 0 |
NCT02091960 | Phase II | Enzalutamide + Trastuzumab | A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer | Active, not recruiting | USA | CAN | 4 |
NCT02131064 | Phase III | Ado-trastuzumab emtansine + Pertuzumab Carboplatin + Docetaxel + Pertuzumab + Trastuzumab | A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer | Completed | USA | CAN | 8 |
NCT02132949 | Phase II | Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil + Pertuzumab + Trastuzumab | A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer | Completed | USA | CAN | 10 |
NCT02139358 | Phase Ib/II | Gemcitabine + Pertuzumab + Trastuzumab | Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer | Completed | USA | 0 |
NCT02152943 | Phase I | Everolimus + Letrozole + Trastuzumab | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | Completed | USA | 0 |
NCT02154529 | Phase Ib/II | Tesevatinib + Trastuzumab | Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | Terminated | USA | 0 |
NCT02167854 | Phase I | Alpelisib + Elgemtumab + Trastuzumab | Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer | Active, not recruiting | USA | 0 |
NCT02187744 | Phase III | Carboplatin + Docetaxel + Trastuzumab | A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | Completed | USA | 9 |
NCT02213042 | Phase II | Lapatinib + Trastuzumab Trastuzumab | Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer | Completed | USA | 11 |
NCT02213744 | Phase II | Trastuzumab + Vinorelbine Capecitabine + Trastuzumab Gemcitabine + Trastuzumab MM-302 + Trastuzumab | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | Terminated | USA | CAN | 7 |
NCT02229149 | Phase II | Paclitaxel Docetaxel Pertuzumab + Trastuzumab Nab-paclitaxel Vinorelbine Trastuzumab Capecitabine | Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT02236000 | Phase Ib/II | Ado-trastuzumab emtansine + Neratinib | A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT02252887 | Phase II | Gemcitabine + Pertuzumab + Trastuzumab | Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy | Active, not recruiting | USA | 0 |
NCT02297230 | Phase Ib/II | Capecitabine Paclitaxel Paclitaxel + Trastuzumab | Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics | Terminated | USA | 0 |
NCT02297698 | Phase II | Sargramostim Trastuzumab E75 | Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients | Active, not recruiting | USA | 0 |
NCT02308020 | Phase II | Abemaciclib | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | Completed | USA | CAN | 7 |
NCT02318901 | Phase Ib/II | Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | Terminated | USA | 0 |
NCT02326974 | Phase II | Ado-trastuzumab emtansine + Pertuzumab | T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA | Active, not recruiting | USA | 0 |
NCT02336984 | Phase Ib/II | Trastuzumab HER2-pulsed DC1 vaccine | A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS | Withdrawn | USA | 0 |
NCT02345772 | Phase I | Fulvestrant Docetaxel + Pertuzumab + Trastuzumab | Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer | Terminated | USA | 0 |
NCT02390427 | Phase I | Trastuzumab Paclitaxel Pertuzumab Taselisib | Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer | Active, not recruiting | USA | 0 |
NCT02402712 | Phase III | Docetaxel + Pertuzumab + Trastuzumab | Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer | Completed | CAN | 11 |
NCT02403271 | Phase Ib/II | Durvalumab + Ibrutinib | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02492711 | Phase III | Vinorelbine Capecitabine Gemcitabine Trastuzumab Eribulin Margetuximab-cmkb | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer | Active, not recruiting | USA | CAN | 16 |
NCT02500199 | Phase I | Pyrotinib | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | Active, not recruiting | USA | 0 |
NCT02536339 | Phase II | Pertuzumab + Trastuzumab | A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy | Active, not recruiting | USA | 0 |
NCT02571530 | Phase I | Trastuzumab | Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer | Recruiting | USA | 0 |
NCT02598427 | Phase I | Pertuzumab + Trastuzumab | Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer | Terminated | USA | 0 |
NCT02605915 | Phase I | Atezolizumab + Trastuzumab Docetaxel Carboplatin Pertuzumab | Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer | Completed | USA | 0 |
NCT02614794 | Phase II | Capecitabine + Trastuzumab + Tucatinib Capecitabine + Trastuzumab | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB) | Active, not recruiting | USA | CAN | 13 |
NCT02649686 | Phase I | Durvalumab + Trastuzumab | Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab | Completed | CAN | 0 |
NCT02650752 | Phase I | Capecitabine + Lapatinib | Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases | Completed | USA | 0 |
NCT02654119 | Phase II | Cyclophosphamide + Paclitaxel + Trastuzumab | Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery | Active, not recruiting | USA | 0 |
NCT02657343 | Phase Ib/II | Ribociclib Trastuzumab Ado-trastuzumab emtansine | An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. | Active, not recruiting | USA | 0 |
NCT02658084 | Phase Ib/II | Ado-trastuzumab emtansine + Vinorelbine | Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer | Terminated | USA | 0 |
NCT02659514 | Phase II | Poziotinib | Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT02673398 | Phase II | Neratinib | Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT02675231 | Phase II | Trastuzumab Abemaciclib + Trastuzumab Abemaciclib + Fulvestrant + Trastuzumab | A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (monarcHER) | Active, not recruiting | USA | CAN | 12 |
NCT02689921 | Phase II | Anastrozole Letrozole Leuprolide Pertuzumab + Trastuzumab Exemestane | NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT) | Unknown status | USA | 0 |
NCT02751528 | Phase I | ETBX-021 | QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer | Unknown status | USA | 0 |
NCT02774681 | Phase II | Trastuzumab Palbociclib | Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis | Terminated | USA | 0 |
NCT02789657 | Phase II | Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin | Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. | Active, not recruiting | USA | 0 |
NCT02827877 | Phase I | Pertuzumab + Trastuzumab | Copper (Cu) 64-DOTA-Trastuzumab PET Imaging in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer | Recruiting | USA | 0 |
NCT02892123 | Phase I | Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | Recruiting | USA | CAN | 1 |
NCT02907918 | Phase II | Goserelin Letrozole + Palbociclib + Trastuzumab | Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN) | Terminated | USA | 0 |
NCT02924883 | Phase II | Trastuzumab Atezolizumab + Trastuzumab | A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy (KATE2) | Completed | USA | CAN | 7 |
NCT02947685 | Phase III | Fulvestrant Pertuzumab Letrozole Anastrozole Exemestane Palbociclib Trastuzumab | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA) | Recruiting | USA | 6 |
NCT03054363 | Phase Ib/II | Letrozole + Palbociclib + Tucatinib | Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT03112590 | Phase Ib/II | Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT03125928 | Phase II | Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | Recruiting | USA | 0 |
NCT03135171 | Phase I | Pertuzumab + Tocilizumab + Trastuzumab | Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab | Recruiting | USA | 0 |
NCT03190967 | Phase Ib/II | Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Temozolomide | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery | Recruiting | USA | 0 |
NCT03284723 | Phase I | Letrozole + Palbociclib + PF-06804103 PF-06804103 | PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors | Recruiting | USA | 5 |
NCT03304080 | Phase Ib/II | Anastrozole + Palbociclib + Pertuzumab + Trastuzumab | Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast | Recruiting | USA | 0 |
NCT03319459 | Phase I | FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT03321981 | Phase II | Letrozole + Zenocutuzumab Anastrozole + Zenocutuzumab Fulvestrant + Zenocutuzumab Exemestane + Zenocutuzumab Trastuzumab + Zenocutuzumab Trastuzumab + Vinorelbine + Zenocutuzumab | MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer | Active, not recruiting | USA | 6 |
NCT03324425 | Phase II | Simvastatin | Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer (SIMPHONY) | Recruiting | USA | 0 |
NCT03329378 | Phase II | Docetaxel + Paclitaxel + Pegfilgrastim + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab | Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer | Suspended | USA | 0 |
NCT03330561 | Phase I | PRS-343 | PRS-343 in HER2-Positive Solid Tumors | Recruiting | USA | 0 |
NCT03364348 | Phase I | Trastuzumab + Utomilumab Ado-trastuzumab emtansine + Utomilumab | 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT03368729 | Phase Ib/II | Niraparib + Trastuzumab | Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | Recruiting | USA | 0 |
NCT03377387 | Phase Ib/II | Capecitabine + Neratinib | Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer | Recruiting | USA | 0 |
NCT03379428 | Phase Ib/II | Trastuzumab Ibrutinib + Trastuzumab | Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT03384914 | Phase II | HER2-pulsed DC1 vaccine pUMVC3-IGFBP2-HER2-IGF1R vaccine | Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer | Recruiting | USA | 0 |
NCT03387553 | Phase I | HER2-pulsed DC1 vaccine | HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer | Recruiting | USA | 0 |
NCT03414658 | Phase II | Avelumab + Trastuzumab + Utomilumab + Vinorelbine Avelumab + Trastuzumab + Vinorelbine Avelumab + Trastuzumab + Utomilumab Trastuzumab + Vinorelbine | The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | Suspended | USA | 0 |
NCT03417544 | Phase II | Atezolizumab + Pertuzumab + Trastuzumab | Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC | Active, not recruiting | USA | 0 |
NCT03429101 | Phase I | Ado-trastuzumab emtansine + Poziotinib | A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer | Terminated | USA | 0 |
NCT03433313 | Phase III | Cyclophosphamide + Epirubicin + Paclitaxel + Trastuzumab Cyclophosphamide + EG12014 + Epirubicin + Paclitaxel | Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer | Active, not recruiting | USA | 10 |
NCT03451162 | Phase I | DHES0815A | Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer | Active, not recruiting | USA | 1 |
NCT03493854 | Phase III | Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer | Active, not recruiting | USA | CAN | 17 |
NCT03501979 | Phase II | Capecitabine + Trastuzumab + Tucatinib | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | Recruiting | USA | 0 |
NCT03521245 | Phase I | Trastuzumab | Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer | Active, not recruiting | USA | 1 |
NCT03523585 | Phase III | Trastuzumab deruxtecan Capecitabine + Lapatinib Capecitabine + Trastuzumab | DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | Active, not recruiting | USA | 14 |
NCT03529110 | Phase III | Trastuzumab deruxtecan Ado-trastuzumab emtansine | DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] | Active, not recruiting | USA | CAN | 13 |
NCT03530696 | Phase II | Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Palbociclib | T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (T-DM1) | Recruiting | USA | 0 |
NCT03564782 | Phase I | PVSRIPO | Examining Bioactivity of PVSRIPO in Invasive Breast Cancer | Recruiting | USA | 0 |
NCT03587740 | Phase II | Ado-trastuzumab emtansine | ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT03620201 | Phase I | M7824 | M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer | Recruiting | USA | 0 |
NCT03630809 | Phase II | HER2-pulsed DC1 vaccine | Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 | Suspended | USA | 0 |
NCT03674112 | Phase II | Pertuzumab + Trastuzumab | A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer | Active, not recruiting | USA | 16 |
NCT03709082 | Phase Ib/II | Ado-trastuzumab emtansine + Letrozole + Palbociclib | Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT03716180 | Phase I | Paclitaxel + Pertuzumab + Trastuzumab | DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | Active, not recruiting | USA | 0 |
NCT03726879 | Phase III | Cyclophosphamide + Doxorubicin Atezolizumab + Cyclophosphamide + Doxorubicin Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab | A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050) | Active, not recruiting | USA | CAN | 11 |
NCT03747120 | Phase II | Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab Paclitaxel + Pembrolizumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab | Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab | Recruiting | USA | 0 |
NCT03765983 | Phase II | GDC-0084 + Trastuzumab | GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases | Recruiting | USA | 0 |
NCT03846583 | Phase I | Abemaciclib + Trastuzumab + Tucatinib | Tucatinib + Abemaciclib + Herceptin for HER2+ MBC | Withdrawn | 0 | |
NCT03975647 | Phase III | Ado-trastuzumab emtansine + Tucatinib Ado-trastuzumab emtansine | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | Recruiting | USA | CAN | 8 |
NCT03983395 | Phase Ib/II | GBR1302 | Study of GBR 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT04042701 | Phase I | Pembrolizumab + Trastuzumab deruxtecan | DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer | Recruiting | USA | 1 |
NCT04054752 | Phase I | NT-I7 | Vaccine Response With NT-I7 | Recruiting | USA | 0 |
NCT04108858 | Phase Ib/II | Copanlisib + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer | Recruiting | USA | 0 |
NCT04120246 | Phase I | alpha-TEA + Trastuzumab | Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT04147819 | Phase I | BAY2701439 | A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein | Recruiting | USA | 1 |
NCT04188548 | Phase I | Abemaciclib + LY3484356 LY3484356 Abemaciclib + LY3484356 + Trastuzumab Abemaciclib + Anastrozole + LY3484356 Abemaciclib + Exemestane + LY3484356 Alpelisib + LY3484356 Everolimus + LY3484356 Abemaciclib + Letrozole + LY3484356 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) | Recruiting | USA | 7 |
NCT04208178 | Phase III | Pertuzumab + Trastuzumab Alpelisib + Pertuzumab + Trastuzumab | Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | Recruiting | USA | 3 |
NCT04224272 | Phase II | Fulvestrant + Palbociclib + ZW25 | A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer | Recruiting | USA | CAN | 1 |
NCT04266249 | Phase II | Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Ado-trastuzumab emtansine Docetaxel + Pertuzumab + Trastuzumab Nab-paclitaxel + Pertuzumab + Trastuzumab | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | Recruiting | USA | 1 |
NCT04296942 | Phase I | FPV-Brachyury + M7824 + MVA-BN-Brachyury Ado-trastuzumab emtansine + Entinostat + FPV-Brachyury + M7824 + MVA-BN-Brachyury Ado-trastuzumab emtansine + FPV-Brachyury + M7824 + MVA-BN-Brachyury | BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) | Recruiting | USA | 0 |
NCT04298918 | Phase Ib/II | Ado-trastuzumab emtansine + Venetoclax Ado-trastuzumab emtansine | A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Active, not recruiting | USA | 8 |
NCT04348747 | Phase II | Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Rintatolimod | Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | Not yet recruiting | USA | 0 |
NCT04351230 | Phase II | Abemaciclib + Ado-trastuzumab emtansine Ado-trastuzumab emtansine | Abemaciclib With or Without T-DM1 for the Treatment of HER2-Positive Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT04395508 | Expanded access | Pertuzumab + Trastuzumab | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | Available | USA | 0 |
NCT04450732 | Phase I | GQ1001 | Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04457596 | Phase III | Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Tucatinib | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | Recruiting | USA | 0 |
NCT04467515 | Phase Ib/II | CAM-H2 | A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer | Not yet recruiting | CAN | 0 |
NCT04509596 | Phase I | DZD1516 + Trastuzumab Capecitabine + DZD1516 Ado-trastuzumab emtansine + DZD1516 Capecitabine + DZD1516 + Trastuzumab DZD1516 | DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer | Recruiting | USA | 0 |
NCT04512261 | Phase Ib/II | Pembrolizumab + Trastuzumab + Tucatinib | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Women With HER2-Positive Breast Cancer Brain Metastases (TOPAZ) | Not yet recruiting | USA | 0 |
NCT04538742 | Phase Ib/II | Durvalumab + Trastuzumab deruxtecan Pertuzumab + Trastuzumab deruxtecan Durvalumab + Paclitaxel + Trastuzumab deruxtecan Paclitaxel + Trastuzumab deruxtecan Trastuzumab deruxtecan | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DB-07) | Recruiting | USA | 9 |
NCT04539938 | Phase II | Trastuzumab deruxtecan + Tucatinib | A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04) | Recruiting | USA | 0 |
NCT04752332 | Phase III | Abemaciclib | A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer (eMonarcHER) | Not yet recruiting | USA | 16 |